Clinical trial Recruiting at 3 sites Interventional Ages 4 Weeks to 8 Weeks

Using diuretic renogram to identify significant obstruction in ureteropelvic junction syndrome

Official title: Cortical Transit Time on Diuretic Renogram as an Early Marker of Significant Obstruction in Antenatally Detected Uretero-pelvic Junction Syndrome

Run by Centre Hospitalier Universitaire de la Réunion · NCT02812212 · Data updated 2026-11-12

This study is testing if a special kidney scan can help doctors tell if infants with ureteropelvic junction obstruction need surgery to prevent kidney damage.

Quick facts

Study typeInterventional
Ages4 Weeks to 8 Weeks
SexAll
Enrollment75 (estimated)
SponsorCentre Hospitalier Universitaire de la Réunion
Academic / other
Locations5 sites (Bordeaux and 4 other locations)
StatusRecruiting
StartedNovember 28, 2017
Main results expectedNovember 2026
Study endsApril 2027
Registry record updatedSeptember 29, 2022
Trial IDNCT02812212 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are infants aged 4 to 8 weeks with antenatally detected unilateral ureteropelvic junction obstruction.

Probably not a fit

Patients with bilateral UPJO, associated contralateral uropathy, or severe disabilities may not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This study evaluates the use of cortical transit time on diuretic renograms as an early marker for significant obstruction in infants diagnosed with ureteropelvic junction obstruction (UPJO) detected antenatally. It aims to differentiate between reversible antenatal hydronephrosis and pathological UPJO, which can lead to renal damage if untreated. The study involves infants aged 4 to 8 weeks who have been diagnosed with UPJO and will undergo ultrasonography and diuretic renography to assess their condition. The goal is to improve the management of UPJO by providing reliable prognostic criteria for surgical intervention.

Why it matters

Potential benefit: If successful, this study could lead to earlier and more accurate identification of significant UPJO, potentially preventing renal damage in affected infants.

How similar studies have gone: While the use of diuretic renography is common, this specific approach to early identification of significant obstruction in UPJO is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

Infants:

* Aged of 4 to 8 weeks of life
* Presenting an ureteropelvic junction obstruction (UPJO) detected before birth by ultrasound
* Presenting an UPJO, defined by an Antero-Posterior Renal Pelvic Diameter greater or equal to 15 mm, confirmed by ultrasound post-natally between the 1st and 15th day of life
* Presenting a unilateral UPJO
* whose legal representatives have provided a signed free and informed written consent for their infant's participation
* whose at least one of his legal representative is affiliated to national social security

Exclusion Criteria:

Infants presenting:

* A bilateral UPJO
* An ureteral dilatation
* An associated contralateral uropathy
* A solitary kidney
* A renal insufficiency
* Severe associated disabilities ( ie polymalformation syndromes)
* A concomitant participation in another trial
* A contraindication to furosemide (acute renal insufficiency, hepatic encephalopathy, hypovolemia or dehydration, severe hypokalemia, severe hyponatremia)
* A contraindication to the radionuclide marker (hypersensitivity to the active substance or to excipients)

Where it's running

  • CHU de Bordeaux
    Bordeaux, France
    Recruiting
  • CHU de Limoges
    Limoges, France
    Recruiting
  • Centre Hospitalier Universitaire de La Réunion
    Saint-Denis, France
    Recruiting
  • CHU de Nantes
    Nantes, France
    Not yet recruiting
  • CHU de Rennes
    Rennes, France
    Not yet recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.